SRPT vs. ANF
Compare and contrast key facts about Sarepta Therapeutics, Inc. (SRPT) and Abercrombie & Fitch Co. (ANF).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SRPT or ANF.
Correlation
The correlation between SRPT and ANF is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
SRPT vs. ANF - Performance Comparison
Loading data...
Key characteristics
SRPT:
-1.00
ANF:
-0.78
SRPT:
-1.76
ANF:
-1.03
SRPT:
0.73
ANF:
0.88
SRPT:
-0.88
ANF:
-0.76
SRPT:
-1.96
ANF:
-1.34
SRPT:
36.01%
ANF:
36.82%
SRPT:
70.54%
ANF:
64.40%
SRPT:
-98.17%
ANF:
-86.59%
SRPT:
-78.80%
ANF:
-61.96%
Fundamentals
SRPT:
$3.81B
ANF:
$3.66B
SRPT:
-$2.64
ANF:
$10.69
SRPT:
159.25
ANF:
-24.52
SRPT:
1.71
ANF:
0.74
SRPT:
3.34
ANF:
2.74
SRPT:
$2.23B
ANF:
$3.93B
SRPT:
$1.81B
ANF:
$2.50B
SRPT:
-$117.73M
ANF:
$756.19M
Returns By Period
In the year-to-date period, SRPT achieves a -68.83% return, which is significantly lower than ANF's -51.05% return. Over the past 10 years, SRPT has underperformed ANF with an annualized return of 3.56%, while ANF has yielded a comparatively higher 16.36% annualized return.
SRPT
-68.83%
-36.29%
-66.82%
-70.19%
-18.04%
-24.11%
3.56%
ANF
-51.05%
-0.81%
-51.86%
-49.84%
56.50%
44.02%
16.36%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SRPT vs. ANF — Risk-Adjusted Performance Rank
SRPT
ANF
SRPT vs. ANF - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Abercrombie & Fitch Co. (ANF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SRPT vs. ANF - Dividend Comparison
Neither SRPT nor ANF has paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SRPT Sarepta Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ANF Abercrombie & Fitch Co. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.98% | 4.63% | 3.99% | 4.59% | 6.67% | 2.96% | 2.79% |
Drawdowns
SRPT vs. ANF - Drawdown Comparison
The maximum SRPT drawdown since its inception was -98.17%, which is greater than ANF's maximum drawdown of -86.59%. Use the drawdown chart below to compare losses from any high point for SRPT and ANF. For additional features, visit the drawdowns tool.
Loading data...
Volatility
SRPT vs. ANF - Volatility Comparison
Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 39.88% compared to Abercrombie & Fitch Co. (ANF) at 14.36%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than ANF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SRPT vs. ANF - Financials Comparison
This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Abercrombie & Fitch Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SRPT vs. ANF - Profitability Comparison
SRPT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 607.29M and revenue of 744.86M. Therefore, the gross margin over that period was 81.5%.
ANF - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Abercrombie & Fitch Co. reported a gross profit of 974.01M and revenue of 1.58B. Therefore, the gross margin over that period was 61.5%.
SRPT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of -300.39M and revenue of 744.86M, resulting in an operating margin of -40.3%.
ANF - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Abercrombie & Fitch Co. reported an operating income of 256.06M and revenue of 1.58B, resulting in an operating margin of 16.2%.
SRPT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of -447.51M and revenue of 744.86M, resulting in a net margin of -60.1%.
ANF - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Abercrombie & Fitch Co. reported a net income of 187.23M and revenue of 1.58B, resulting in a net margin of 11.8%.